Annals of Internal MedicineGabapentinoids and Risk for Severe Exacerbation in Chronic Obstructive Pulmonary Disease

A Population-Based Cohort Study

A recent study conducted on the effects of gabapentinoid use in individuals with chronic obstructive pulmonary disease (COPD) has revealed significant insights. The research, drawing on data from the Régie de l’assurance maladie du Québec health insurance databases, specifically investigates the association between gabapentinoid use and the risk of severe exacerbations in COPD patients.

Study Design:

• Participants: Patients with COPD between 1994 and 2015, including 356 gabapentinoid users with epilepsy, 9411 with neuropathic pain, and 3737 with other chronic pain.
• Study Type: Time-conditional propensity score–matched, new-user cohort study.
• Data Source: Health insurance databases from the Régie de l’assurance maladie du Québec in Canada.
• Matching Criteria: COPD duration, indication for gabapentinoids, age, sex, calendar year, and time-conditional propensity score.
• Outcome Measurement: Primary outcome was severe COPD exacerbation requiring hospitalization.

Key Findings:

• Increased Risk: Gabapentinoid use associated with increased risk of severe COPD exacerbation across all indications.
• Hazard Ratios: Epilepsy (HR, 1.58), neuropathic pain (HR, 1.35), other chronic pain (HR, 1.49), and overall (HR, 1.39).
• 95% Confidence Intervals: Varied across indications but consistently showed increased risk.
• Limitation Noted: Potential residual confounding due to lack of smoking information.

HCN Medical Memo
This study holds particular importance in light of recent warnings by North American and European health agencies regarding the potential respiratory risks associated with gabapentinoids.

More on Gabapentin